Arix Bioscience looks to boost the cutting edge of biotech

0
13
  • Arix Bioscience concludes strategic review, reshuffles board
test tubes

LSE:ARIX

Market: LSE
Market Cap: GBP253.9 m
Follow

View company profile

Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

The company collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients.

As a listed company, it aims to bring this growth phase of the industry to a broader range of investors.

30 Apr 2021

() updated investors on the outcome of its strategic review and unveiled a number of board changes.

The biotech-focused venture capital firm said it has completed its stakeholder engagement and “now has a clear understanding of shareholder views”, which it said will enable it to implement its strategy more effectively.

Arix said it appointed its chief operating officer and general counsel Robert Lyne to the board with immediate effect and that he will act as interim chief executive while the company recruited a permanent replacement.

The group also said its executive chairman Naseem Amin has left the firm with immediate effect and named Peregrine Moncreiffe as non-executive chairman, while it appointed Maureen O’Connell and Isaac Kohlberg as non-executive directors, both of which were nominated by the company’s largest shareholder Corp.

Read more

28 Apr 2021

() said one of its portfolio companies, Amplyx Pharmaceuticals, is to be acquired by US pharma giant Inc () in a deal it said will result in a small increase to its holding in the firm.

Amplyx, which develops therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. The company’s lead drug compound, Fosmanogepix (APX001), is under development for the treatment of invasive fungal infections.

Read more

27 Apr 2021

() said portfolio company LogicBio Therapeutics, Inc. (NASDAQ:LOGC) has signed a strategic collaboration with CANbridge Pharmaceuticals as well as a research partnership with Daiichi Sankyo.

Under the terms of the agreement with CANbridge Pharmaceuticals, LogicBio is eligible to receive an upfront payment of US$10mln in addition to up to US$581mln in option payments and milestones, plus up to double-digit royalties.

Read more

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Arix Bioscience (LON:ARIX) Presenting at the Proactive One2One Virtual Forum…

Arix Bioscience (LON:ARIX) Presenting at the Proactive One2One Virtual Forum 8th April 2021

Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional…

3 weeks, 1 day ago

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here